MOUNTAIN VIEW, Calif., July 22, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) ("VIVUS"), which recently began selling the obesity drug Qsymia ® (phentermine and topiramate extended-release) capsules CIV in the United States, today announced that its Board of Directors has appointed Michael Astrue to serve as its Chairman and Anthony Zook to serve as its Chief Executive Officer, effective today. Mr. Astrue formerly served as Chief Executive Officer of Transkaryotic Therapies, Chairman of the Massachusetts Biotechnology Council, and Commissioner of Social Security. Mr. Zook formerly served as Executive Vice President , Global Commercial Operations for AstraZeneca and President of Medimmune.
VIVUS Board Selects Michael Astrue As Chairman And Tony Zook As CEO
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts